Evaluation of acute and early cardiotoxicity in survivors of Hodgkin's disease treated with ABVD or BEACOPP regimens
Language English Country Great Britain, England Media print
Document type Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Acute Disease MeSH
- Bleomycin adverse effects therapeutic use MeSH
- Cyclophosphamide adverse effects therapeutic use MeSH
- Dacarbazine adverse effects therapeutic use MeSH
- Adult MeSH
- Doxorubicin adverse effects therapeutic use MeSH
- Echocardiography MeSH
- Etoposide adverse effects therapeutic use MeSH
- Ventricular Function, Left MeSH
- Hodgkin Disease drug therapy MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Heart Diseases chemically induced diagnostic imaging MeSH
- Prednisone adverse effects therapeutic use MeSH
- Survivors * MeSH
- Procarbazine adverse effects therapeutic use MeSH
- Prospective Studies MeSH
- Antineoplastic Combined Chemotherapy Protocols adverse effects therapeutic use MeSH
- Vinblastine adverse effects therapeutic use MeSH
- Vincristine adverse effects therapeutic use MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Bleomycin MeSH
- Cyclophosphamide MeSH
- Dacarbazine MeSH
- Doxorubicin MeSH
- Etoposide MeSH
- Prednisone MeSH
- Procarbazine MeSH
- Vinblastine MeSH
- Vincristine MeSH
The study was conducted to compare the presence of cardiotoxicity after the treatment of Hodgkin's disease with the standard ABVD or BEACOPP protocol. We examined 29 patients treated by means of the ABVD regimen and 34 treated with the BEACOPP regimen. Using rest echocardiography we assessed the left ventricular function before and after the therapy. One year after the completion of therapy, a control examination was performed with a battery of tests; the rest and dynamic stress echocardiography and cardiopulmonary tests were carried out to assess cardiopulmonary performance. A similar significant deterioration of ejection fraction and diastolic function was apparent after the treatment in both sub-groups with a further progression at the one-year control. Only one patient from the BEACOPP sub-group showed a pathological drop of EF <50%. The most affected parameters of left ventricular function (LV) were Doppler indices. We found a significant relationship of the parameters of LV function compared with age, the cumulative dose of doxorubicin and the cumulative dose of radiotherapy. Multivariate analysis demonstrated that diastolic dysfunction correlated with advanced age and the cumulative dose of doxorubicin, and decreased cardiopulmonary performance with advanced age, radiotherapy, and female gender. Both parameters were significantly influenced by the presence of hypertension. The used regimens demonstrated similar subclinical cardiotoxicity, thus the most aggressive regimen, BEACOPP, is not accompanied by a higher rate of cardiac impairment. The clinical value of such subclinical cardiotoxicity will be estimated in a further prospective follow-up.
References provided by Crossref.org